CAJ | 학술논문

背景与目的：上皮性卵巢癌是最常见的卵巢肿瘤类型，发病率高，治疗效果不满意，生存率低。CXXC指蛋白5(CXXC finger protein 5，CXXC5)在上皮性卵巢癌中的研究鲜见报道，该研究通过对CXXC5在上皮性卵巢癌中的表达和对上皮性卵巢癌细胞功能的研究，旨在探讨CXXC5在上皮性卵巢癌中可能的作用和临床意义。方法：①通过肿瘤基因图集(The Cancer Genoma Atlas，TCGA)数据库提供的数据分析CXXC5在上皮性卵巢癌基因组中的变异；②通过免疫组织化学法(immunohistochemistry，IHC)检测CXXC5在上皮性卵巢癌组织芯片中的表达情况，并分析CXXC5的表达与临床病理特征之间的关系；③通过蛋白[质]印迹法(Western blot)和实时定量PCR(real-time quantitative PCR，qRT-PCR)检测CXXC5在5株上皮性卵巢癌细胞系中的表达情况，选取表达量最高的ES-2细胞株；④使用慢病毒包装质粒转染ES-2细胞株，经嘌呤霉素筛选后构建稳定转染干扰细胞株；使用细胞计数试剂盒(cell counting kit-8，CCK8)检测细胞增殖能力的变化。结果：①CXXC5在TCGA提供的上皮性卵巢癌基因组中以表达为主；②CXXC5在上皮性卵巢和卵巢良性上皮性囊肿中的高表达率分别为39.3%和13.5%，差异有统计学意义(P=0.003)；CXXC5在浆液性卵巢癌、黏液性卵巢癌、子宫内膜样卵巢癌和卵巢透明细胞癌中的高表达率分别为43.0%、22.9%、23.5%和66.7%，两两比较差异均有统计学意义(P均=0.014)；CXXC5在有淋巴结转移和无淋巴结转移的上皮性卵巢癌中表达率为60.0%和35.8%，差异有统计学意义(P=0.022)；③CXXC5稳定干扰后，卵巢癌透明细胞株ES-2的增殖能力明显减弱，差异有统计学意义(P<0.05)。结论：CXXC5基因可能有促进卵巢癌细胞增殖的作用，可能是上皮性卵巢癌预后不良的生物标志物。
배경여목적：상피성란소암시최상견적란소종류류형，발병솔고，치료효과불만의，생존솔저。CXXC지단백5(CXXC finger protein 5，CXXC5)재상피성란소암중적연구선견보도，해연구통과대CXXC5재상피성란소암중적표체화대상피성란소암세포공능적연구，지재탐토CXXC5재상피성란소암중가능적작용화림상의의。방법：①통과종류기인도집(The Cancer Genoma Atlas，TCGA)수거고제공적수거분석CXXC5재상피성란소암기인조중적변이；②통과면역조직화학법(immunohistochemistry，IHC)검측CXXC5재상피성란소암조직심편중적표체정황，병분석CXXC5적표체여림상병리특정지간적관계；③통과단백[질]인적법(Western blot)화실시정량PCR(real-time quantitative PCR，qRT-PCR)검측CXXC5재5주상피성란소암세포계중적표체정황，선취표체량최고적ES-2세포주；④사용만병독포장질립전염ES-2세포주，경표령매소사선후구건은정전염간우세포주；사용세포계수시제합(cell counting kit-8，CCK8)검측세포증식능력적변화。결과：①CXXC5재TCGA제공적상피성란소암기인조중이표체위주；②CXXC5재상피성란소화란소량성상피성낭종중적고표체솔분별위39.3%화13.5%，차이유통계학의의(P=0.003)；CXXC5재장액성란소암、점액성란소암、자궁내막양란소암화란소투명세포암중적고표체솔분별위43.0%、22.9%、23.5%화66.7%，량량비교차이균유통계학의의(P균=0.014)；CXXC5재유림파결전이화무림파결전이적상피성란소암중표체솔위60.0%화35.8%，차이유통계학의의(P=0.022)；③CXXC5은정간우후，란소암투명세포주ES-2적증식능력명현감약，차이유통계학의의(P<0.05)。결론：CXXC5기인가능유촉진란소암세포증식적작용，가능시상피성란소암예후불량적생물표지물。
Background and purpose:Epithelial ovarian cancer has the highest mortality rate of gynecologic cancers and overall survival rates have improved little in the last 20 to 30 years. CXXC ifnger protein 5 (CXXC5) plays an important role in AML (acute myeloid leukemia) and MDS (myelodysplasia). However, little is known about its clinical signiifcance and biological function in epithelial ovarian cancer. This study aimed to investigate the expression of the CXXC5 in ovarian cancer and the effect of the CXXC5 on ES-2 cell proliferation. Methods:①The alteration of CXXC5 in cancer genomics data of TCGA (Cancer Genome Atlas) was analyzed.②The CXXC5 protein in the tissue chips was detected containing 37 benign ovarian cyst and 173 malignant tumor samples. The relationship between the expression of the CXXC5 with the clinicopathological features of patients with ovarian cancer was analyzed by SPSS software;③The cells with the highest CXXC5 expression quantity from 5 ovarian cancer cells were selected by re-al-time quantitative PCR (qRT-PCR) and Western blot.④ES-2 cells with shRNA stable transfection were construted us-ing the strategy of lentivirus infection and analyzed cell proliferation by cell counting kit-8(CCK8). Results:①Through the TCGA database, CXXC5 ampliifcation was found in 7 of 563 cases.②The CXXC5 expression in ovarian malignant carcinoma (39.3%) was higher than that in benign ovarian cyst (13.5%, P=0.003), the histologic type was highly asso-ciated with CXXC5 (43%in serous, 22.9%in mucinous, 23.5%in endometrioid, 67%in clear cell, P=0.014) and there was a signiifcant correlation between CXXC5 and lymph node metastasis (positive vs negative, P=0.022).③The ES-2 cells with shRNA stable transfection had a growth disadvantage (P<0.05). Conclusion:The CXXC5 gene might have an advantage in proliferation of epithelial ovarian carcinoma and be expected to become the biomarker of poor prognosis.